Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals

Search By

☰ Generic Formulas

Generic Formulas X

Gentamicin

Gentamicin: A Comprehensive Overview

Introduction

Gentamicin is an aminoglycoside antibiotic used for the treatment of various bacterial infections, particularly those caused by gram-negative bacteria. It is one of the most commonly prescribed parenteral antibiotics for serious infections and is often used in hospitals due to its broad-spectrum activity and effectiveness against resistant organisms. Despite its powerful antimicrobial activity, gentamicin has a narrow therapeutic index, meaning that its use requires careful monitoring to avoid toxicity.

Gentamicin

Gentamicin is a broad-spectrum aminoglycoside that was first discovered in 1963. It is derived from Micromonospora purpurea, a type of soil bacterium. Gentamicin is effective against a wide range of aerobic gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. Additionally, it has some activity against gram-positive bacteria when used in combination with other antibiotics. Gentamicin is available in parenteral forms, such as intravenous (IV) and intramuscular (IM) injections, as well as in ophthalmic formulations for treating eye infections. It is frequently used in the hospital setting, particularly for patients with serious systemic infections like sepsis and pneumonia.

Mechanism of Action

Gentamicin, like other aminoglycosides, works by inhibiting protein synthesis in bacterial cells. Its mechanism of action involves binding to the 30S ribosomal subunit, leading to:

1. Inhibition of Protein Synthesis:

By binding to the 30S subunit of bacterial ribosomes, gentamicin disrupts the mRNA decoding process, leading to the incorporation of incorrect amino acids into the growing peptide chain. This results in non-functional proteins that are unable to carry out essential cellular functions.

2. Disruption of Membrane Integrity:

Gentamicin can also cause membrane damage in bacteria, contributing to bacterial cell death. The disruption of membrane integrity increases the permeability of the cell membrane, allowing gentamicin to penetrate the bacteria and exert its effects.

3. Bactericidal Effect:

Gentamicin’s action is bactericidal, meaning it kills bacteria rather than simply inhibiting their growth. This makes it highly effective against rapidly multiplying bacteria, particularly in serious infections.

Due to these actions, gentamicin is particularly effective against aerobic gram-negative bacteria, which rely heavily on their ribosomes for protein synthesis.

Indications and Uses

Gentamicin is used to treat a wide variety of serious bacterial infections. Some of the most common indications for its use include:

1. Urinary Tract Infections (UTIs):

Gentamicin is effective in treating complicated UTIs caused by resistant or severe pathogens such as Pseudomonas aeruginosa and Escherichia coli.

2. Sepsis:

Gentamicin is often used in combination therapy to treat sepsis, particularly when caused by gram-negative organisms. It is particularly important in severe infections, where rapid bacterial eradication is essential.

3. Respiratory Infections:

Gentamicin is used to treat hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), particularly when resistant bacteria are involved.

4. Abdominal Infections:

It is indicated for peritonitis, intra-abdominal abscesses, and diverticulitis, where infections may be caused by gram-negative organisms that are sensitive to gentamicin.

5. Bone and Joint Infections:

Gentamicin can be used in combination with other antibiotics to treat osteomyelitis and septic arthritis, particularly in cases where gram-negative bacteria are implicated.

6. Ophthalmic Infections:

Gentamicin is available in ophthalmic formulations for treating eye infections such as conjunctivitis or keratitis, typically caused by gram-negative bacteria.

Pharmacokinetics

Gentamicin has a unique pharmacokinetic profile that is important for clinicians to understand when prescribing the drug. Below are the key pharmacokinetic properties:

Absorption:

Gentamicin is poorly absorbed from the gastrointestinal tract, so it is typically administered parenterally (IV or IM). When given via IV injection, it achieves rapid and high plasma concentrations.

Distribution:

After intravenous administration, gentamicin is widely distributed throughout the extracellular space. It has poor penetration into tissues such as the central nervous system (CNS) and bone, which limits its use in treating infections of those areas.
However, it does achieve high concentrations in the kidneys, lungs, and urinary tract, making it particularly useful in treating UTIs and respiratory infections.

Metabolism:

Gentamicin is not extensively metabolized in the liver, and it remains largely unchanged in the blood, making it ideal for treating infections in the kidneys.

Excretion:

Renal excretion is the primary route of elimination for gentamicin. It is eliminated by glomerular filtration, which means that the drug’s elimination depends on renal function. This is important because renal toxicity can occur if gentamicin accumulates in the body due to impaired kidney function.

Half-Life:

The half-life of gentamicin is approximately 2 to 3 hours in individuals with normal renal function. This short half-life requires frequent dosing, particularly in serious infections.

Dosing and Administration

Gentamicin’s dosing regimen is highly dependent on the severity of the infection, the patient’s age, weight, and renal function. It is typically administered either intravenously (IV) or intramuscularly (IM). Some key considerations for dosing include:

Standard Dosing:

For most infections, the recommended initial dose of gentamicin is around 3 to 5 mg/kg/day, divided into two to three doses.

Renal Adjustments:

Gentamicin dosing must be adjusted for patients with renal impairment. For those with creatinine clearance (CrCl) less than 30 mL/min, the dose should be reduced, or the dosing interval should be extended to prevent accumulation and toxicity.

Monitoring:

Because gentamicin has a narrow therapeutic index, its blood levels need to be closely monitored. The peak concentration (the highest level of the drug) should be measured about 30 minutes after the infusion. The trough concentration (the lowest level of the drug before the next dose) should be measured just before the next dose.
The therapeutic range for peak levels is typically between 5 and 10 mcg/mL, and for trough levels, it should be less than 2 mcg/mL to avoid nephrotoxicity.

Side Effects and Adverse Reactions

Despite its effectiveness, gentamicin can cause significant adverse effects, particularly when used for prolonged periods or in high doses. Some common and serious side effects include:

Common Side Effects:

Nausea, vomiting, and diarrhea.
Rash and fever.
Injection site pain and redness.

Serious Adverse Effects:

Nephrotoxicity: Gentamicin can cause kidney damage, particularly in patients with pre-existing renal issues. It is most often seen with prolonged therapy or high cumulative doses. Renal function should be monitored regularly.
Ototoxicity: Gentamicin has the potential to cause hearing loss or balance issues (vestibular toxicity). This is particularly a concern in elderly patients or those receiving high doses or prolonged therapy.
Neuromuscular Blockade: In rare cases, gentamicin can cause muscle weakness and respiratory depression, especially when used with neuromuscular blocking agents during surgery.

Hypersensitivity Reactions:

Allergic reactions, including rash, angioedema, and anaphylaxis, can occur but are less common.

Contraindications and Precautions

Contraindications:

Hypersensitivity to gentamicin or other aminoglycosides.
Renal failure with high serum creatinine levels.

Precautions:

Pregnancy: Gentamicin is classified as a Category D drug, meaning it may cause harm to the fetus and should only be used if the benefits outweigh the risks.
Elderly Patients: Older adults may be more susceptible to ototoxicity and nephrotoxicity, requiring careful monitoring.
Neuromuscular Diseases: Use with caution in patients with myasthenia gravis or other neuromuscular disorders due to the risk of muscle weakness.

Conclusion

Gentamicin remains a cornerstone in the treatment of serious infections, particularly those caused by gram-negative bacteria. Its bactericidal activity and broad-spectrum effectiveness make it a valuable antibiotic in the hospital setting. However, its potential for causing nephrotoxicity and ototoxicity underscores the need for careful dosing, regular monitoring, and consideration of renal function. When used appropriately, gentamicin can significantly improve outcomes for patients with life-threatening infections. By adhering to appropriate dosing schedules and closely monitoring for side effects, healthcare providers can optimize the therapeutic benefits of gentamicin while minimizing its risks.